RANKL is a mediator of bone resorption in idiopathic hypercalciuria

RANKL is a mediator of bone resorption in idiopathic hypercalciuria

Autor Gornes, Sarnirah Abreu Autor UNIFESP Google Scholar
Reis, Luciene Machado dos Google Scholar
Noronha, Irene Lourdes Google Scholar
Jorgetti, Vanda Google Scholar
Heilberg, Ita Pfeferman Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
Resumo Background and objectives: This study aimed to determine the expression of osteoprotegerin, receptor activator of nuclear factor kappa B ligand, interleukin-la, transforming growth factor-beta, and basic fibroblast growth factor in stone-forming patients with idiopathic hypercalciuria.Design, setting, participants, & measurements: Immunohistochemical analysis was performed in undecalcified bone samples previously obtained from 36 transiliac bone biopsies of patients who had idiopathic hypercalciuria and whose histomorphometry had shown lower bone volume, increased bone resorption, and prolonged mineralization lag time.Results: Bone expression of receptor activator of nuclear factor kappa B ligand and osteoprotegerin was significantly higher in patients with idiopathic hypercalciuria versus control subjects. Transforming growth factor-beta immunostaining was lower in patients with idiopathic hypercalciuria than in control subjects and correlated directly with mineralization surface. Interleukin-la and basic fibroblast growth factor staining did not differ between groups. Receptor activator of nuclear factor kappa B ligand bone expression was significantly higher in patients who had idiopathic hypercalciuria and exhibited higher versus normal bone resorption.Conclusion: A higher expression of receptor activator of nuclear factor kappa B ligand in bone tissue suggests that increased bone resorption in patients with idiopathic hypercalciuria is mediated by receptor activator of nuclear factor kappa B ligand. Osteoprotegerin bone expression might have been secondarily increased in an attempt to counteract the actions of receptor activator of nuclear factor kappa B ligand. the low bone expression of transforming growth factor-beta could contribute to the delayed mineralization found in such patients.
Idioma Inglês
Financiador Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Número do financiamento FAPESP: 03/09271-5
FAPESP: 03/05652-4
Data de publicação 2008-09-01
Publicado em Clinical Journal of the American Society of Nephrology. Washington: Amer Soc Nephrology, v. 3, n. 5, p. 1446-1452, 2008.
ISSN 1555-9041 (Sherpa/Romeo, fator de impacto)
Publicador Amer Soc Nephrology
Extensão 1446-1452
Fonte http://dx.doi.org/10.2215/CJN.00240108
Direito de acesso Acesso aberto Open Access
Tipo Artigo
Web of Science WOS:000258757500035
Endereço permanente http://repositorio.unifesp.br/handle/11600/30873

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta